J. Bennett

H. Deeg, J. Bennett, S. Gore, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Adult acute leukemia. The Rochester (NY) Experience.

J. Bennett, R. Enck, A. Bauman, 1976, Archives of internal medicine.

Oncology Group (E1996) prospective randomized phase 3 trial by the Eastern Cooperative with or without granulocyte colony-stimulating factor: results of a Treatment of myelodysplastic syndrome patients with erythropoietin

D. Cella, P. Greenberg, J. Bennett, 2013 .

Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).

D. Cella, P. Greenberg, J. Bennett, 2009, Blood.

Anthracycline dose intensification in acute myeloid leukemia.

J. Bennett, M. Tallman, G. Dewald, 2009, The New England journal of medicine.

J. Leonard, J. Bennett, K. Jhaveri, 2007, Leukemia research.

A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases

I. Baumann, J. Bennett, D. Head, 2003, Leukemia.

Acute myelogenous leukemia and aging. Clinical interactions.

C. Willman, J. Bennett, J. Lancet, 2000, Hematology/oncology clinics of North America.

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.

H. Döhner, P. Vyas, H. Kantarjian, 2021, The Lancet. Oncology.

Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience.

R. Gray, N. Robert, W. Wood, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Melphalan may be a more potent leukemogen than cyclophosphamide.

L. Melton, M. Greene, G. Malkasian, 1986, Annals of internal medicine.

Fibrosis and Subsequent Cytopenias Are Associated with Basic Fibroblast Growth Factor–Deficient Pluripotent Mesenchymal Stromal Cells in Large Granular Lymphocyte Leukemia

Sheng Wei, G. Bloom, J. Bennett, 2013, The Journal of Immunology.

Enhancing geriatric oncology training to care for elders: A clinical initiative with long term follow-up

J. Bennett, W. Hall, L. Balducci, 2010 .

Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995.

J. Bennett, M. Tallman, L. Cripe, 2000, Leukemia research.

Acute leukemia with t(10;11)(p11-p15;q13-q23).

J. Bennett, E. Paietta, C. Secco, 1996, Cancer genetics and cytogenetics.

Cancer patient accessions into clinical trials: a pilot investigation into some patient and physician determinants of entry.

J. Bennett, J. Mccusker, A. Wax, 1982, American journal of clinical oncology.

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

J. Issa, H. Kantarjian, G. Garcia-Manero, 2008, Cancer.

Revised international prognostic scoring system for myelodysplastic syndromes.

Luca Malcovati, Pierre Fenaux, Mario Cazzola, 2012, Blood.

Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes.

J. Bennett, J. Lancet, E. Padron, 2020, Clinical lymphoma, myeloma & leukemia.

Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes.

A. Stamatoullas, J. Bennett, P. Fenaux, 2019, Leukemia research.

Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS.

M. Cazzola, F. Solé, M. L. Le Beau, 2018, Leukemia research.

New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types.

J. Bennett, U. Germing, R. Haas, 2017, Leukemia research.

Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines

C. Bloomfield, R. Bejar, P. Greenberg, 2015 .

Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group

F. Solé, M. L. Le Beau, T. Brümmendorf, 2015, Haematologica.

Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group

F. Solé, M. L. Le Beau, K. Götze, 2015, Genes, chromosomes & cancer.

Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)

M. Cazzola, F. Solé, M. L. Beau, 2015, Leukemia.

Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher‐risk myelodysplastic syndromes

G. Mufti, B. Skikne, J. Bennett, 2014, British journal of haematology.

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)

P. Greenberg, J. Bennett, P. Fenaux, 2014, Blood Cancer Journal.

Morphological classification of the myelodysplastic syndromes: how much more education of diagnosticians is necessary?

J. Bennett, 2013, Haematologica.

14 Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS (IWG-PM)

M. Cazzola, F. Solé, A. Levis, 2011 .

Syndromes Revised International Prognostic Scoring System for Myelodysplastic

M. Cazzola, F. Solé, A. Levis, 2012 .

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

B. Skikne, J. Bennett, S. Nimer, 2013, Leukemia.

Consensus statement on iron overload in myelodysplastic syndromes

J. Bennett, 2008, American journal of hematology.

Phase 2 study of lenalidomide in transfusion-dependent , low-risk , and intermediate-1 – risk myelodysplastic syndromes with karyotypes other than deletion 5 q

J. Reeves, H. Deeg, P. Greenberg, 2007 .

Myelodysplastic syndromes clinical practice guidelines in oncology.

C. Bloomfield, M. Millenson, H. Deeg, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

Informed consent to treatment in clinical trials.

J. Bennett, G. Morrow, P. Carpenter, 1983, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Anemia in the elderly

J. Bennett, W. Ershler, L. Balducci, 2007 .

A 17‐Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy

P. Febbo, S. Raman, D. Elashoff, 2018, The Journal of urology.

Characterization of acute promyelocytic leukemia cases with PML-RAR alpha break/fusion sites in PML exon 6: identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acid.

J. Bennett, M. Tallman, E. Paietta, 1995, Blood.

A Presenter ’ s POV : ASH Meeting on Hematologic Malignancies

F. O. Hoffman, J. Bennett, 2022 .

Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: Results of the multicenter MDS-003 Study

P. Greenberg, J. Bennett, G. Dewald, 2005 .

Adriamycin and cytoxan in the treatment of inoperable lung cancer

S. Lagakos, J. Bennett, J. Macintyre, 1983, Cancer.

A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate.

J. Bennett, N. Cross, J. Baxter, 2004, Leukemia research.

Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS.

B. Bain, G. Mufti, J. Bennett, 2011, Leukemia research.

Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface.

J. Bennett, C. Fonatsch, P. Valent, 2007, Leukemia research.

Diagnosis and treatment of systemic mastocytosis: state of the art

J. Bennett, P. Valent, D. Metcalfe, 2003, British journal of haematology.

Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin.

A. Verma, J. Maciejewski, J. Bennett, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

5 – THE LYMPHOMAS

J. Bennett, 1981 .

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

M. Grever, I. Flinn, D. Neuberg, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High‐dose dexamethasone for refractory or relapsing multiple myeloma

A. Tsiatis, M. Oken, R. Kyle, 1991, American journal of hematology.

Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group.

D. Catovsky, J. Bennett, G. Flandrin, 1985, Annals of internal medicine.

Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy.

J. Glick, J. Bennett, C. Berard, 1981, Blood.

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions

L. Pleyer, T. Haferlach, A. Órfão, 2019, Haematologica.

Phase II study of mitoguazone, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with diffuse histologic subtypes of non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Study (PE481).

M. Oken, D. Moore, J. Glick, 1998, Leukemia & lymphoma.

Burkitt's Tumor

J. Bennett, P. Carbone, J. Ziegler, 1969 .

Long‐term survival in acute myeloid leukemia

J. Bennett, M. Tallman, E. Paietta, 1997, Cancer.

L. Van Hove, J. Bennett, G. Flandrin, 1993, Leukemia & lymphoma.

Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study.

D. Neuberg, P. Greenberg, A. Cherry, 2003, Leukemia research.

Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria.

J. Bennett, P. Valent, D. Metcalfe, 2003, Leukemia research.

A phase II study of phenesterin (NSC-104469).

S. Lagakos, J. Bennett, J. Horton, 1978, Medical and pediatric oncology.

Carcinocythemia (carcinoma cell leukemia). An acute leukemia-like picture due to metastatic carcinoma cells.

J. Bennett, R. Carey, S. Kaufman, 1976, The American journal of medicine.

A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer

J. Doroshow, J. Bennett, C. Vogel, 1985, Investigational New Drugs.

Acute leukaemias of ambiguous lineage. .

M. Borowitz, J. Bennett, G. Flandrin, 2001 .

Autologous bone marrow transplant in acute myeloid leukemia in first remission.

M. Oken, J. Bennett, O. Colvin, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

J. Bennett, P. Fenaux, E. Hellström-Lindberg, 2013, Haematologica.

Management of malignant pleural effusion

J. Bennett, D. Greenwald, Clay Phillips, 1978, Journal of surgical oncology.

A Case of Acute Eosinophilic Leukemia with a Novel PHF6 Mutation

P. Rothberg, J. Bennett, C. Zent, 2021, Case reports in hematology.

Nodular histiocytic lymphoma: Factors influencing prognosis and implications for aggressive chemotherapy

J. Glick, E. McFadden, J. Bennett, 1982, Cancer.

Diffuse well‐differentiated lymphocytic lymphoma (DLWD). Response and survival

J. Bennett, P. Carbone, C. Berard, 1978, Cancer.

Treatment of histiocytic and mixed lymphomas. A comparison of two, three and four drug chemotherapy

J. Bennett, R. Lenhard, J. Wolter, 1978, Cancer.

Survival of nodular versus diffuse pattern lymphocytic poorly differentiated lymphoma

J. Bennett, R. Lenhard, P. Carbone, 1978, Cancer.

Pathology Panel for Lymphoma Clinical Studies: a comprehensive analysis of cases accumulated since its inception.

R. Hartsock, J. Bennett, C. Berard, 1982, Journal of the National Cancer Institute.

Increased Concentrations of SerumFreeFattyAcidsFalsely IncreaseSerumThyroxine as Determined byCompetitive Protein- Binding

J. Bennett, P. Pannall, E. Swanepoel, 1977 .

Phase III Prospective Randomized Trial of EPO with or without G-CSF Versus Supportive Therapy Alone in the Treatment of Myelodysplastic Syndromes (MDS): Results of the ECOG- CLSG Trial(E1996).

P. Greenberg, J. Bennett, M. Tallman, 2004 .

Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome

D. Gilliland, J. Bennett, J. Prchal, 2000 .

A European consensus report on blood cell identification: terminology utilized and morphological diagnosis concordance among 28 experts from 17 countries within the European LeukemiaNet network WP10, on behalf of the ELN Morphology Faculty

B. Bain, T. Haferlach, A. Porwit, 2010, British journal of haematology.

S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes

W. Hiddemann, J. Bennett, T. Büchner, 1997, Annals of Hematology.

Comparison of intensive versus moderate chemotherapy of lymphocytic lymphomas. A progress report

S. Pocock, J. Bennett, R. Lenhard, 1976, Cancer.

Myelodysplastic syndromes standardized response criteria: further definition.

B. Cheson, P. Greenberg, H. Kantarjian, 2001, Blood.

Bleomycin, Lomustine, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BLEO-CCVPP) in Patients with Hodgkin's Disease who Relapsed after Radiotherapy Alone: a Long-Term Foliow-Up Study of the Eastern Cooperative Oncology Group (E3481)

T. Habermann, M. Oken, J. Glick, 2001, Leukemia & lymphoma.

The Leukemia-Lymphoma Cell Line Facts Book

J. Bennett, 2002 .

Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung.

S. Lagakos, G. Wampler, J. Edmonson, 1976, Cancer treatment reports.

Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly.

C. Begg, J. Glick, J. Bennett, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trials with procarbazine (NSC-77213), streptozotocin (NSC-85998), 6-THIOGUANINE (NSC-752), and CCNU (NSC-79037) in patients with metastatic cancer of the large bowel.

J. Hanley, J. Bennett, J. Horton, 1975, Cancer chemotherapy reports.

The FAB/MIC/WHO proposals for the classification of the chronic lymphoid leukemias.

J. Bennett, 2002, Reviews in clinical and experimental hematology.

Are myelodysplastic syndromes and acute myeloid leukemia one disease?

J. Bennett, R. Gale, 2009, Leukemia research.

E. Jaffe, S. Lewis, D. Catovsky, 1985, Clinical and laboratory haematology.

Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias

K. Foon, J. Bennett, 2012, Cancer Treatment and Research.

Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes

Rainer Haas, John M. Bennett, J. Bennett, 2008, Annals of Hematology.

Clinical benefit and survival endpoints from a phase III trial comparing decitabine (DAC) vs supportive care (SC) in patients with advanced myelodysplastic syndromes (MDS)

J. Issa, J. Dipersio, H. Kantarjian, 2005 .

Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature.

J. Messina, J. Bennett, J. Lancet, 2012, Leukemia research.

Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

W. Wiktor-Jedrzejczak, G. Mufti, G. Gaidano, 2012 .

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.

J. Byrd, G. Mufti, J. Bennett, 2007 .

Age and Hodgkin's disease: the impact of competing risks and possibly salvage therapy on long term survival: an E.C.O.G. study.

C. Begg, J. Glick, J. Bennett, 1993, Leukemia research.

Who Has Therapy-Related AML?

F. O. Hoffman, J. Bennett, R. Gale, 2017, Mediterranean journal of hematology and infectious diseases.

Pentostatin induces durable remissions in hairy cell leukemia.

M. O’connell, J. Bennett, D. Harrington, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Time-dependent decision analysis: Stable disease in azacitidine (AZA)-treated patients (pts) with higher-risk MDS.

J. Bennett, P. Fenaux, E. Hellström-Lindberg, 2010 .

Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission

G. Mufti, J. Bennett, P. Fenaux, 2008 .

NCCN practice guidelines for the myelodysplastic syndromes

E. Estey, P. Greenberg, J. Bennett, 1998 .

John M Bennett, J. Armitage, J. Connors, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acute myeloid leukemia and other myelopathic disorders following treatment with alkylating agents.

M. Greene, J. Bennett, J. Boice, 1987, Hematologic pathology.

Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes

M. Cazzola, F. Solé, M. L. Beau, 2015 .

Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

B. Skikne, J. Bennett, S. Nimer, 2015, Leukemia.

Myelodysplastic/Myeloproliferative Diseases (Overlap Syndromes)

J. Bennett, C. Hanson, 2007 .

Long-Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome and Chromosome Deletion 5q.

P. Greenberg, J. Bennett, S. Nimer, 2006 .

Myelodysplastic syndromes: introduction.

J. Bennett, G. Flandrin, D. Head, 2001 .

Appelbaum FR, Rowe JM, Radich J, Dick JE. Acute Myeloid Leukemia. Hematology Am Soc Hematol Educ Program. 2001:62-86. PMID: 11722979

E. Campo, P. Greenberg, J. Bennett, 2008 .

The selective use of AMSA following high‐dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup Study

R. Day, R. Larson, J. Bennett, 1992, British journal of haematology.

PROLONGED SURVIVAL IN HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) PATIENTS (PTS) WITH-7/DEL(7Q) TREATED WITH AZACITIDINE (AZA)

G. Mufti, B. Quesnel, G. Garcia-Manero, 2008 .

Myelodysplastic syndromes: clinical practice guidelines in oncology.

C. Bloomfield, M. Millenson, H. Deeg, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival.

J. Bennett, T. Matsuo, J. Goasguen, 1992, Leukemia.

The myelodysplastic syndromes: Diagnosis, molecular biology and risk assessment

J. Bennett, R. Komrokji, 2005, Hematology.

Reference standards for bone marrow cellularity.

J. Bennett, N. Tuzuner, J. M. Bennett, 1994, Leukemia research.

Coalescence of the German-Austrian and IMRAW Cytogenetic MDS Databases: Modification of Patient Risk Groups.

C. Steidl, M. L. Beau, P. Greenberg, 2007 .

Chronic lymphocytic leukemia: recommendations.

M. Grever, B. Cheson, M. Oken, 1989, Annals of internal medicine.

Group 3999 leukemia : a randomized , placebo-controlled trial of the Eastern outcome of older patients with newly diagnosed acute myeloid Zosuquidar , a novel modulator of P-glycoprotein

H. Uno, J. Bennett, M. Tallman, 2010 .

Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up--a report from the Eastern Cooperative Oncology Group.

L. Gordon, J. Winter, M. Oken, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Very poor long‐term survival in past and more recent studies for relapsed AML patients: The ECOG‐ACRIN experience

M. O’connell, J. Bennett, M. Tallman, 2018, American journal of hematology.

Advances in the therapy of the myelodysplastic syndromes.

J. Bennett, P. Kouides, 1999, Cancer treatment and research.

Time Changes In Predictive Power Of MDS Prognostic Scores – Effects On Revised Scores Such As The IPSS-R, Impact Of Age

M. Cazzola, F. Solé, A. Levis, 2013 .

Emergence of JAK2-mutant primary myelofibrosis in myelodysplastic syndrome: rare case report, literature review, and implications for clonal progression

J. Bennett, W. R. Burack, J. Liesveld, 2012, Journal of Hematopathology.

Acute myeloid leukaemia expressing the leucocyte integrin CD11b-a new leukaemic syndrome with poor prognosis: result of an ECOG database analysis. Eastern Cooperative Oncology Group.

J. Bennett, M. Tallman, J. Yunis, 1998, British journal of haematology.

Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses.

J. Bennett, J. Yunis, E. Paietta, 1994, Leukemia.

Treatment of Relapsed and Refractory AML with Mitoxantrone and Etoposide: A Study of the Eastern Cooperative Oncology Group

J. Bennett, J. Rowe, J. Mazza, 1994 .

The second international congress on myeloproliferative and myelodysplastic syndromes.

J. Bennett, R. Silver, R. Silverstein, 2004, Leukemia research.

Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes

W. Hiddemann, J. Bennett, C. Fonatsch, 1999, Journal of Cancer Research and Clinical Oncology.

Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentary.

J. Bennett, J. Vardiman, R. Brunning, 2002, Blood.

Anti-Angiogenic In Vivo Effect of Lenalidomide (CC-5013) in Myelodysplastic Syndrome with del(5q) Chromosome Abnormality and Its Relation to the Course of Disease.

J. Bennett, H. Kreipe, A. Giagounidis, 2005 .

C005 New definitions for blast cells in AML and MDS with validation by virtual microscopy

B. Bain, G. Mufti, J. Bennett, 2007 .

Refractory anaemia with excess blasts.

N. Harris, J. Bennett, G. Flandrin, 2001 .

Treatment of metastatic breast cancer with aminoglutethimide

J. Bennett, E. Savlov, R. Asbury, 1981, Cancer.

A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies

C. Bloomfield, H. Gundacker, S. Raimondi, 2006, Leukemia.

Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900

O. Abdel-Wahab, R. Levine, J. Bennett, 2018, Haematologica.

Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an eastern cooperative oncology group trial (E4995)

J. Bennett, M. Tallman, G. Dewald, 2005, Leukemia & lymphoma.

The prognosis and therapy of chronic lymphocytic leukemia under age 50 years.

P. Rubin, M. Oken, J. Bennett, 1988, Nouvelle revue francaise d'hematologie.

Phase III Evaluation of Low-Dose Cytosine Arabinoside Versus Supportive Care in the Treatment of Adults With Myelodysplastic Syndrome: An Intergroup Study by the Eastern Cooperative Oncology Group and the Southwest Oncology Group—Preliminary Results

J. Winter, J. Bennett, D. Head, 1992 .

Medical Surveillance for Leukemia at a Petrochemical Manufacturing Complex: Four-Year Summary

J. Bennett, C. Ross, S. Cowles, 1991, Journal of occupational medicine. : official publication of the Industrial Medical Association.

Reclassification of leukemia among A-bomb survivors in Nagasaki using French-American-British (FAB) classification for acute leukemia.

N. Kamada, J. Bennett, M. Tomonaga, 1988, Japanese journal of clinical oncology.

Nodular mixed lymphocytic‐histiocytic lymphoma (NM) response and survival

J. Bennett, R. Lenhard, P. Carbone, 1980, Cancer.

Eastern cooperative oncology group experience with the rappaport classification of non‐Hodgkin's lymphomas

R. Hartsock, J. Bennett, R. Lenhard, 1979, Cancer.

A variant form of hypergranular promyelocytic leukemia (M3)

H. Gralnick, D. Catovsky, J. Bennett, 1980, Annals of internal medicine.

Clinical use of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in neutropenia associated with malignancy.

R. Lifton, J. Bennett, Robin Lifton, 1996, Hematology/oncology clinics of North America.

Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group.

J. Thompson, J. Bennett, J. Prchal, 2000, Blood.

Syndromes International Scoring System for Evaluating Prognosis in Myelodysplastic

G. Mufti, P. Greenberg, J. Bennett, 2010 .

THE USE OF ‘CHOP’ IN THE TREATMENT OF CLL: A CORRECTION

J. Bennett, 1990, British journal of haematology.

Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group.

M. Oken, J. Bennett, E. Paietta, 1992, Leukemia.

Acute myeloid leukaemia with an unusual phenotype: myeloperoxidase (+), CD13 (‐), CD14 (‐) and CD33 (‐)

J. Bennett, A. Kashyap, B. Seshi, 1992, British journal of haematology.

Lymphoid lineage‐associated features in acute myeloid leukaemia: phenotypic and genotypic correlations

B. Ness, J. Bennett, E. Paietta, 1992, British journal of haematology.

Reply to Gassas et al

I. Baumann, J. Bennett, D. Head, 2003, Leukemia.

The significance of bone marrow involvement in non-Hodgkin's lymphoma: the Eastern Cooperative Oncology Group experience.

K. Cain, J. Glick, M. O’connell, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

B-Lymphoblastic Leukemia/Lymphoma

J. Bennett, G. Flandrin, D. Head, 2014 .

The myelodysplastic/myeloproliferative disorders: the interface.

J. Bennett, 2003, Hematology/oncology clinics of North America.

12 Updated cytogenetic risk features in MDS – present state

C. Steidl, F. Solé, P. Greenberg, 2009 .

Uncommon of the uncommon: low-grade myelodysplastic syndrome evolving into chronic myelogenous leukemia.

J. Bennett, L. Moscinski, Ling Zhang, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adult acute lymphocytic leukemia: the Eastern Cooperative Oncology Group experience.

J. Bennett, E. Paietta, J. Mazza, 1992, Leukemia.

Acute myeloid leukaemia not otherwise categorised. .

N. Harris, J. Bennett, G. Flandrin, 2001 .

Hematology meeting, New Orleans, LA, December 1999. Group experience : Presented in part at the American Society of Acute megakaryocytic leukemia: the Eastern Cooperative Oncology

D. Neuberg, M. Oken, J. Bennett, 2013 .

Use of cell surface antigen phenotype in guiding therapeutic decisions in chronic myelomonocytic leukemia.

J. Bennett, B. Seshi, R. Sham, 1994, Leukemia research.

DNA image cytometry in MDS bone marrow smears

J. Bennett, G. Auer, S. Widell, 1999, British journal of haematology.

Myelodysplastic Syndromes and Aplastic Anemia: Pathologic and Immunologic Implications

J. Bennett, 2008 .

Refractory anaemia with ringed sideroblasts

N. Harris, J. Bennett, G. Flandrin, 2001 .

Results of a Prospective Multicenter Phase II Study of Initial Treatment with Methotrexate In LGL Leukemia (ECOG Protocol E5998)

J. Bennett, M. Tallman, A. Evens, 2010 .

Prolymphocytic leukemia: Histologic findings in atypical cases

J. Bennett, J. Rowe, J. Strauchen, 1984, Hematological oncology.

Acquired Acute Hemolytic Anemia Secondary to Phenazopyridine

J. Bennett, J. Loughner, 1980 .

Mannitol retention during diuretic treatment of barbiturate and salicylate overdosage.

J. Bennett, A. Polak, A. G. Morgan, 1968, The Quarterly journal of medicine.

MYELODYSPLASTIC SYNDROMES : REVISED PROGNOSTIC SCORING SYSTEM

J. Bennett, 2012 .

Prophylactic antibiotics for the prevention of early infection in multiple myeloma.

M. Oken, J. Bennett, D. Weisdorf, 1996, The American journal of medicine.

Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.

J. Bennett, J. Horton, W. Mietlowski, 1982, Cancer treatment reports.

Morphologic dysplasia in acute myeloid leukemia: importance of granulocytic dysplasia.

J. Bennett, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hodgkin's disease. IIB or not to be--using irradiation alone or in combination with chemotherapy? That is the question!

P. Rubin, L. Constine, J. Bennett, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Proposal for a new risk model in myelodysplastic syndrome (MDS) that accounts for events not considered in the original International Prognostic Scoring System (IPSS)

J. Issa, H. Kantarjian, J. Cortes, 2008 .

Morphologic, Immunologic, and Cytogenetic Classification of the Chronic (Mature) B and T Lymphoid Leukemias: Fourth Meeting of the MIC Cooperative Study Group

C. Mecucci, G. Juliusson, J. Bennett, 1990 .

P-119 Advanced myelodysplastic syndromes (MDS): Patient subset results of a phase III trial comparing decitabine (DAC) vs. supportive care (SC)

J. Issa, J. Dipersio, H. Kantarjian, 2005 .

The clinical implications of the World Health Organization's classification of myelodysplastic syndromes.

J. Bennett, R. Komrokji, 2005, Current hematology reports.

P-121 Lenalidomide (CC-5013; revlimid™)-inducedred blood cell (RBC) transfusion-independence (TI) responses in low-/INT-1-risk patients with myelodysplastic syndromes (MDS): Results of the multicenter mds 002 study

J. Reeves, J. Bennett, G. Dewald, 2005 .

Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.

J. Kirkwood, M. Oken, J. Bennett, 2003, Cancer.

C028 Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion

J. Bennett, G. Dewald, A. List, 2007 .

Comparison of postremission therapies in adult acute myeloid leukemia: preliminary analysis of an ECOG study. Eastern Cooperative Oncology Group.

M. O’connell, J. Bennett, D. Harrington, 1990, Haematology and blood transfusion.

Precursor T lymphoblastic leukaemia/lymphoblastic lymphoma. (Precursor T-cell acute lymphoblastic leukaemia). .

S. Swerdlow, M. Borowitz, J. Bennett, 2001 .

Bone-marrow biopsy in Hodgkin's disease.

H. Gralnick, V. Devita, J. Bennett, 1968, The New England journal of medicine.

Chemotherapy for metastatic merkel cell carcinoma

J. Bennett, T. George, P. Di Anthony Sant'Agnese, 1985, Cancer.

Adriamycin in the treatment of far-advanced lung cancer.

S. Lagakos, J. Bennett, P. Carbone, 1976, Cancer treatment reports.

Phase II clinical trial of carboplatin in relapsed and refractory leukemia.

M. Oken, J. Bennett, D. Harrington, 1992, Leukemia.

Aclacinomycin A and etoposide (VP-16-213): an effective regimen in previously treated patients with refractory acute myelogenous leukemia.

J. Bennett, J. Rowe, A. Chang, 1988, Blood.

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

H. Deeg, R. Bejar, P. Greenberg, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease

J. Bennett, W. Vermaak, J. Ubbink, 1991, Klinische Wochenschrift.

Case 5-1998: bone marrow blasts in chronic myelomonocytic leukemia.

J. Bennett, 1998, The New England journal of medicine.

Editorial: Acute leukemia of megakaryocyte lineage (M7)☆

J. Bennett, T. Matsuo, 1988 .

Clinical Utility of Classical and Nonclassical Monocyte Percentage in the Diagnosis of Chronic Myelomonocytic Leukemia

J. Bennett, W. R. Burack, P. C. Leary, 2018, American journal of clinical pathology.

Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999.

H. Uno, J. Bennett, M. Tallman, 2010, Blood.

Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.

J. Bennett, M. Tomonaga, T. Kohno, 1996, Leukemia research.

Escalating the intensity of postremission therapy improves the outcome in acute myeloid leukemia: The ECOG experience

M. O’connell, J. Bennett, D. Harrington, 1992 .

Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group.

M. O’connell, J. Bennett, D. Harrington, 1992, Leukemia.

Burkitt's leukemia with precursor B-cell immunophenotype and atypical morphology (atypical Burkitt's leukemia/lymphoma): case report and review of literature.

J. Bennett, J. Lancet, R. Komrokji, 2003, Leukemia research.

Medical oncology and geriatric medicine

J. Bennett, W. Hall, W. Hall, 1997, Cancer.

A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia.

J. Bennett, M. Tallman, G. Dewald, 2006, Haematologica.

Secondary acute myeloid leukemia.

J. Bennett, 1995, Leukemia research.

Myelodysplastic syndrome and acute myeloid leukemia secondary to mitolactol treatment in patients with breast cancer.

A. Troxel, R. Gelman, J. Bennett, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effectiveness of attenuated chemotherapy in myelodysplastic syndromes: a preliminary report.

J. Bennett, M. Owens, 1988, Medical and pediatric oncology.

Cyclophosphamide, cytosine arabinoside and methotrexate versus cytosine arabinoside and thioguanine for acute non‐lymphocytic leukemia in adults

M. S. Tobin, M. Oken, J. Bertino, 1980, Cancer.

Lymphoblastic leukaemia.

E. Henderson, J. Bennett, 1969, British medical journal.

The cytochemistry of acute leukemia: observations on glycogen and neutral fat in bone marrow aspirates.

J. Bennett, T. Dutcher, T. F. Dutcher, 1969, Blood.

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.

C. Bloomfield, M. Grever, B. Cheson, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.

F. Appelbaum, C. Willman, J. Bennett, 1998, The New England journal of medicine.

The myelodysplastic syndromes: a personal recollection of four decades of classification and prognostic scoring systems

J. Bennett, 2013, Leukemia & lymphoma.

Changes in physicians' attitudes toward telling the cancer patient.

R. L. Smith, J. Bennett, G. Morrow, 1979, JAMA.

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.

I. Bernstein, E. Estey, I. Bernstein, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group.

D. Neuberg, J. Bennett, M. Tallman, 2004, Blood.

Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin).

M. O’connell, J. Bennett, D. Harrington, 1987, The New England journal of medicine.

Diagnostic criteria and classification of mastocytosis: a consensus proposal.

K. Lennert, K. Wolff, R. Parwaresch, 2001, Leukemia research.

A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).

J. Bennett, E. Paietta, J. Rowe, 1995, Blood.

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Valeria Santini, Robert Schoch, Pierre Fenaux, 2009, The Lancet. Oncology.

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

C. Bloomfield, E. Estey, W. Hiddemann, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia.

C. Begg, J. Glick, J. Bennett, 1984, Blood.

Combination chemotherapy in accelerated phase of chronic granulocytic leukemia.

J. Bennett, P. Carbone, H. Foley, 1969, Archives of internal medicine.

The Acquisition of Granulocytes by Leukapheresis: A Comparison of Continuous Flow Centrifugation and Filtration Leukapheresis in Normal and Corticosteroid‐Stimulated Donors

J. Bennett, J. Macpherson, J. Nusbacher, 2003, Transfusion.

An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.

M. Carroll, P. Crooks, J. Bennett, 2007, Blood.

Non‐Hodgkin's lymphoma and acute myeloblastic leukemia. A report of 12 cases and review of the literature

J. Bennett, F. Rosner, M. Zarrabi, 1979, Cancer.

Defective granulocyte regulation in the Chediak-Higashi syndrome.

J. Bennett, S. Wolff, R. Yankee, 1968, The New England journal of medicine.

Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference.

T. Haferlach, A. Órfão, P. Greenberg, 2007, Leukemia research.

Classification of Acute Leukemia

D. A. G. Galton, John M. Bennett, H. Gralnick, 1977 .

Phase I clinical and pharmacokinetic study of diethyldithiocarbamate as a chemoprotector from toxic effects of cisplatin.

T. Montine, J. Bennett, P. Dedon, 1988, Journal of the National Cancer Institute.

Cytogenetic findings in erythroleukemia.

J. Whang‐Peng, C. Heath, J. Bennett, 1969, Blood.

Vasectomy: an update.

J. Bennett, Paul L Dassow, 2006, American family physician.

The myelodysplastic syndromes: diagnosis and treatment.

J. Bennett, D. Steensma, 2006, Mayo Clinic proceedings.

The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study

J. Winter, M. O’connell, J. Bennett, 1992, Annals of Hematology.

The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study

J. Winter, M. O’connell, J. Bennett, 2005, Annals of Hematology.

Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Joseph R. Bertino, Colin B. Begg, Pierre R. Band, 1980, The American journal of medicine.

Varying intensity of postremission therapy in acute myeloid leukemia.

M. Oken, M. O’connell, J. Bennett, 1992, Blood.

Acute Leukemia Cytochemical Profile: Diagnostic and Clinical Implications

J. Bennett, C. E. Reed, 1975 .

A Close Association of Autoimmune-Mediated Processes and Autoimmune Disorders with Chronic Myelomonocytic Leukemia: Observation from a Single Institution

J. Bennett, J. Lancet, L. Moscinski, 2014, Acta Haematologica.

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

B. Cheson, P. Greenberg, H. Kantarjian, 2000, Blood.

Decitabine improves patient outcomes in myelodysplastic syndromes

John M Bennett, J. Issa, Lanlan Shen, 2006, Cancer.

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

J. Reeves, H. Deeg, P. Greenberg, 2008, Blood.

Myelodysplastic syndromes.

C. Bloomfield, M. Millenson, H. Deeg, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

B. Cheson, P. Greenberg, H. Kantarjian, 2006, Blood.

Nonspherocytic Haemolytic Anaemia with Increased Red Cell Adenine Nucleotides, Glutathione and Basophilic Stippling and Ribosephosphate Pyrophosphokinase (RPK) Deficiency: Studies on Two New Kindreds

J. Bennett, W. Krivit, W. Valentine, 1973, British journal of haematology.

Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia

B. Sikic, J. Bennett, M. Tallman, 1999, Cancer.

The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French ‐ American ‐ British Cooperative Leukaemia Group

H. Gralnick, D. Catovsky, J. Bennett, 1994, British journal of haematology.

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

M. Grever, B. Cheson, J. Bennett, 1996, Blood.

Classification of the Acute Leukemias: Cytochemical and Morphologic Considerations

J. Bennett, N. Tuzuner, 2013 .

A Randomized Trial of Induction Therapy (Daunorubicin, Vincristine, Prednisone versus Daunorubicin, Vincristine, Prednisone, Cytarabine and 6-Thioguanine) in Adult Acute Lymphoblastic Leukemia with Long-term Follow-up: An Eastern Cooperative Oncology Group Study (E3486)

M. Oken, J. Bennett, E. Paietta, 2003, Leukemia & lymphoma.

New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.

C. Steidl, F. Solé, M. L. Le Beau, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience.

D. Neuberg, M. Oken, J. Bennett, 2000, Blood.

Controversies in the Management of Lymphomas

J. Bennett, 1983, Cancer Treatment and Research.

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

P. Greenberg, J. Bennett, R. Stone, 2006, The New England journal of medicine.

Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias.

A. Ferrando, D. Neuberg, A. Look, 2004, Blood.

Long term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group (ECOG) experience.

J. Bennett, P. Cassileth, J. Andersen, 1991, Leukemia research.

Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group.

H. Gralnick, D. Catovsky, J. Bennett, 1989, Journal of clinical pathology.

Bone marrow lymphocytosis in acute leukemia: a second look.

E. Henderson, J. Bennett, R. Skeel, 1970, Blood.

The significance of bone marrow lymphocytosis of acute leukemia patients in remission.

E. Henderson, J. Bennett, R. Skeel, 1968, Blood.

Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia.

M. Oken, M. O’connell, J. Bennett, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase I Pilot Study for the Eastern Cooperative Oncology Group.

M. O’connell, J. Bennett, D. Adelstein, 1985, Seminars in oncology.

Combination Chemotherapy of Chronic

J. Bennett, H. Foley, 1969 .

Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial.

J. Kahn, J. Bennett, A. Levine, 1991, JAMA.

Rare adult acute lymphocytic leukemia with CD56 expression in the ECOG experience shows unexpected phenotypic and genotypic heterogeneity

D. Neuberg, J. Bennett, S. Richards, 2001, American journal of hematology.

Pathogenetic implications of internuclear bridging in myelodysplastic syndrome. An eastern cooperative oncology group/southwest oncology group cooperative study

M. Grever, J. Bennett, D. Head, 1989, Cancer.

Phase II study of theophylline in chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E4998)

J. Bennett, M. Tallman, E. Paietta, 2004, Leukemia.

Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).

R. Advani, P. Greenberg, B. Sikic, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine.

M. Kaplan, J. Bennett, S. Kornblau, 1995, The New England journal of medicine.

Recommendations for a morphologic, immunologic, and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders. Report of the workshop held in Scottsdale, Arizona, USA, on February 23-25, 1987. Third MIC Cooperative Study Group.

J. Bennett, 1988, Cancer genetics and cytogenetics.

Home dialysis does cost less than outpatient dialysis.

J. Bennett, R. Asbury, L. Boros, 1982 .

Unexpected immunoglobulin light chain gene rearrangements in myeloid antigen positive acute lymphoid leukemia.

B. Ness, J. Bennett, B. V. Van Ness, 1991, Leukemia research.

Hemophagocytic lymphohistiocytosis masquerading as progressive chronic lymphocytic leukemia.

J. Friedberg, J. Bennett, D. Kilari, 2013, Leukemia research reports.

Giant neutrophil granules in the Chediak-Higashi syndrome of man, mink, cattle and mice.

J. Bennett, S. Wolff, G. Padgett, 1969, Canadian journal of comparative medicine : Revue canadienne de medecine comparee.

Characterization and significance of abnormal leukocyte granules in the beige mouse: a possible homologue for Chediak-Higashi Aleutian trait.

J. Bennett, S. Wolff, R. Blume, 1969, The Journal of laboratory and clinical medicine.

N-acetyl-beta-glucosaminidase activity in normal and malignant leukocytes.

J. Bennett, C. E. Reed, 1975, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia.

C. Begg, J. Bennett, J. Mazza, 1987, Cancer treatment reports.

Effi cacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised , open-label , phase III study

J. Byrd, G. Mufti, J. Bennett, 2012 .

Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.

J. Vose, A. Zelenetz, M. Kaminski, 2005, Blood.

Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin.

M. Grever, I. Flinn, B. Cheson, 2000, Blood.

Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study.

M. Grever, T. Habermann, J. Bennett, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nitroblue tetrazolium test in Hodgkin disease and other malignant lymphomas.

J. Bennett, J. C. Chang, J. Appleby, 1974, Archives of internal medicine.

THE USE OF ‘CHOP’ IN THE TREATMENT OF CLL

J. Bennett, 1990 .

Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia

T. Habermann, M. Oken, J. Bennett, 1992, British journal of haematology.

Iron deficiency anemia.

J. Bennett, Shersten Killip, M. Chambers, 2007, American family physician.

Burkitt's tumor in the United States

J. Bennett, C. Vogel, P. Carbone, 1969, Cancer.

Time-dependent changes in mortality and transformation risk in MDS.

M. Cazzola, F. Solé, M. L. Le Beau, 2016, Blood.

Myelodysplastic syndromes, version 2.2015.

C. Bloomfield, H. Deeg, R. Bejar, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

The comparison of total body irradiation vs chlorambucil and prednisone for remission induction of active chronic lymphocytic leukemia: an ECOG study. Part I: total body irradiation-response and toxicity.

C. Begg, P. Rubin, J. Bennett, 1981, International journal of radiation oncology, biology, physics.

Phase II study of α2 interferon in the treatment of the chronic myeloproliferative disorders (E5487)

J. Kirkwood, M. Oken, J. Bennett, 2003 .

Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working group

M. Grever, B. Cheson, M. Oken, 1988, American journal of hematology.

Dyserythropoiesis in the diagnosis of the myelodysplastic syndromes and other myeloid neoplasms: problem areas

B. Bain, J. Bennett, M. Tomonaga, 2018, British journal of haematology.

Quality control initiative on the evaluation of the dysmegakaryopoiesis in myeloid neoplasms: Difficulties in the assessment of dysplasia.

B. Bain, J. Bennett, M. Tomonaga, 2016, Leukemia research.

Proposal for refining the definition of dysgranulopoiesis in acute myeloid leukemia and myelodysplastic syndromes.

B. Bain, J. Bennett, M. Tomonaga, 2014, Leukemia research.

Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach

J. Bennett, A. Orazi, 2009, Haematologica.

Morphology and classification of myelodysplastic syndromes.

J. Bennett, P. Kouides, 1992, Hematology/oncology clinics of North America.

Successful embolization of a coronary arterial fistula.

J. Bennett, E. Maree, 1989, International journal of cardiology.

Remission of anti-TIF1γ dermatomyositis after allogeneic hematopoietic stem cell transplant for myelodysplastic syndrome.

J. Bennett, O. Aljitawi, Bushra Tbakhi, 2020, Blood advances.

Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

C. Begg, P. Band, P. Lavin, 1980, The American journal of medicine.

Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia.

J. Bennett, J. Kolitz, A. Lundberg, 2010, Leukemia research.

Classification of the myelodysplastic syndromes.

J. Bennett, 1986, Clinics in haematology.

Spherocytic Hemolytic Anemia and Acute Cholecystitis caused by Clostridium welchii.

J. Bennett, P. Healey, 1963 .

Incidence of Infections in Adult Patients (> 55 Years) with Acute Myeloid Leukemia Treated with Yeast-Derived GM-CSF (Sargramostim): Results of a Double-Blind Prospective Study by the Eastern Cooperative Oncology Group

J. Bennett, J. Anderson, E. Paietta, 1996 .

A phase II trial of VP 16–213 in adults with refractory acute myeloid leukemia: An Eastern Cooperative Oncology Group study

M. Oken, J. Glick, J. Bennett, 1984, American journal of clinical oncology.

Morphology and classification of the myelodysplastic syndromes and their pathologic variants.

J. Bennett, P. Kouides, John M. Bennett, 1996, Seminars in hematology.

Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid.

E. Estey, J. Bennett, D. Douer, 2001, Blood.

Aclarubicin in the Treatment of Refractory Acute Leukemias

J. Bennett, J. Rowe, A. Chang, 1990 .

Mitoxantrone and etoposide in patients with relapsed and refractory acute nonlymphocytic leukemia.

J. Bennett, J. Rowe, M. Oken, 1990, Haematology and blood transfusion.

Concurrence of B-lymphoblastic leukemia and myeloproliferative neoplasm with copy neutral loss of heterozygosity at chromosome 1p harboring a MPL W515S mutation.

P. Papenhausen, J. Bennett, J. Lancet, 2014, Cancer Genetics.

Post-remission therapy in adults with acute myelogenous leukemia: the Eastern Cooperative Oncology Group (ECOG) experience.

M. Oken, J. Bennett, J. Rowe, 1992, Leukemia.

Induction and Post-Remission Therapy in Acute Myeloid Leukemia: Experience of the Eastern Cooperative Oncology Group (ECOG)

J. Bennett, M. Tallman, J. Rowe, 1998 .

Amonafide L-Malate (AS1413) in Combination with Cytarabine Is Equally Effective in Older and Younger Patients with Secondary Acute Myeloid Leukemia (AML); Final Data From a Phase II Study.

J. Bennett, R. Stone, A. Lundberg, 2009 .

Treatment-Relate d M yelodysplasia a nd A cute L eukemia i n Non-Hodgkin's L ymphoma P atients

J. Armitage, J. Connors, J. Bennett, 2003 .

The Myelodysplastic Syndromes: Morphology, risk assessment, and clinical management (2002)

J. Bennett, S. Forman, P. Kouides, 2002, International journal of hematology.

P-104 Outcomes by IPSS-R in lenalidomide-treated patients with IPSS low-/Int-1-risk MDS With del(5q) in MDS-003 and MDS-004: A retrospective analysis

M. Cazzola, P. Greenberg, G. Garcia-Manero, 2013 .

Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey.

J. Sloan, P. Novotny, J. Bennett, 2008, Leukemia research.

Working Group (IWG) response criteria in myelodysplasia Clinical application and proposal for modification of the International

P. Greenberg, H. Kantarjian, J. Bennett, 2009 .

World Health Organization classification of the acute leukemias and myelodysplastic syndrome.

J. Bennett, J M Bennett, J. Bennett, 2000, International journal of hematology.

Half-body and local chest irradiation as consolidation following response to standard induction chemotherapy for disseminated small cell lung cancer: an Eastern Cooperative Oncology Group pilot report.

P. Rubin, J. Bennett, C. Scarantino, 1980, International journal of radiation oncology, biology, physics.

Systemic upper half-body irradiation plus local chest irradiation as consolidation following chemotherapy induction treatment for disseminated small-cell lung cancer

P. Rubin, M. Feldstein, J. Bennett, 1979 .

Marrow transplantation for acute nonlymphoblastic leukemia.

C. Begg, J. Bennett, P. Cassileth, 1980, The New England journal of medicine.

The French-American-British Classification of the Acute Adult Myeloid Leukemias: Its Clinical Relevance

J. Bennett, 1982 .

Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: a report from the Eastern Cooperative Oncology Group.

J. Bennett, M. Tallman, G. Dewald, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.

O. Abdel-Wahab, R. Levine, J. Bennett, 2016, Blood.

A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility.

H. Korman, S. Eggener, J. Bennett, 2019, Urology.

Trilineage extramedullary myeloid cell tumor in myelodysplastic syndrome.

J. Bennett, J. Prchal, C. Listinsky, 1997, Archives of pathology & laboratory medicine.

Cytogenic studies in metastatic neuroblastoma.

J. Whang‐Peng, J. Bennett, 1968, American journal of diseases of children.

Anticipatory nausea and vomiting with chemotherapy.

J. Bennett, J. Arseneau, G. Morrow, 1982, The New England journal of medicine.

Clinical Trials Adults with Acute Myelogenous Leukemia: Experience of the Eastern Cooperative Oncology Group

J. Bennett, J. Rowe, P. Cassileth, 1994 .

patIents comparing indoramin treatment of black Double-blind study propranolol in the with hypertension

J. Bennett, H. Schoeman, D. Welch, 1988 .

Dysplastic erythroid precursors in the myelodysplastic syndromes and the acute myeloid leukemias: Is there biologic significance? (How should blasts be counted?).

J. Bennett, U. Germing, C. Strupp, 2016, Leukemia research.

F. O. Hoffman, J. Bennett, R. Gale, 2014, Leukemia research.

Myelomonocytic leukemias: A historical review and perspectives

J. Bennett, 1971, Cancer.

Myelodysplastic syndromes associated with isolated del(5q) chromosome abnormality ("5q- syndrome"). .

N. Harris, J. Bennett, G. Flandrin, 2001 .

Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492.

D. Neuberg, S. Horning, J. Bennett, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chronic myelomonocytic leukemia in the light of the WHO proposals.

J. Bennett, U. Germing, R. Haas, 2007, Haematologica.

Radiation therapy compared with chemotherapy for consolidation of chemotherapy-induced remission of advanced Hodgkin lymphoma: a study by the Eastern Co-operative Oncology Group (E1476) with >20 years follow-up

J. Glick, J. Bennett, F. Hong, 2009, Leukemia & lymphoma.

VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).

C. Begg, J. Glick, J. Bennett, 1979, Cancer treatment reports.

Sequential cyclophosphamide‐prednisone and vincristine‐bleomycin (CPOB). An effective, schedule‐dependent treatment for advanced diffuse histiocytic lymphoma

M. Oken, J. Glick, J. Bennett, 1983, Cancer.

Current pathology practices in and barriers to MDS diagnosis.

J. C. Williamson, J. Bennett, B. S. Burton, 2013, Leukemia research.

Hypocellular myelodysplastic syndromes (MDS): new proposals

J. Bennett, N. Tuzuner, J. Rowe, 1995, British journal of haematology.

Morphological evaluation of monocytes and their precursors

John M Bennett, B. Bain, G. Mufti, 2009, Haematologica.

Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: Case series and literature review.

J. Bennett, W. R. Burack, J. Liesveld, 2012, Leukemia research.

Morphologic classification of acute myeloid leukemia: concordance among Eastern Cooperative Oncology Group investigators: a comment.

J. Bennett, E. Paietta, P. Cassileth, 1996, Leukemia.

Eastern Cooperative Oncology Group study of the cytochemistry of adult acute myeloid leukemia by correlation of subtypes with response and survival.

C. Begg, J. Bennett, 1981, Cancer research.

Phase II study of mitoxantrone in advanced breast cancer: an Eastern Cooperative Oncology Group pilot study.

J. Glick, J. Bennett, K. Pandya, 1984, Cancer treatment reports.

T-cell large granular lymphocyte proliferation in myelodysplastic syndromes: Clinicopathological features and prognostic significance.

J. Bennett, L. Moscinski, Ling Zhang, 2016, Leukemia research.

Cell cycle and clinical characteristics of patients with acute myeloid leukemia and myelodysplasia whose biopsies are reactive with anti-factor VIII antibody

R. Larson, J. Bennett, G. Browman, 1991 .

Morphologic dysplasia in Myelodysplastic Syndromes: How accurate are morphologists?

J. Bennett, 2018, Leukemia research.

What Is “WHO“? Myelodysplastic Syndromes Classification

J. Bennett, R. Komrokji, 2008 .

High peripheral blast count in adult acute myelogenous leukemia is a primary risk factor for CNS leukemia.

C. Begg, J. Bennett, P. Cassileth, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of myeloperoxidase positivity of blast cells in acute myeloblastic leukemia without maturation (FAB: M1): an ECOG study.

J. Bennett, T. Matsuo, C. Cox, 1989, Hematologic pathology.

Bone marrow cellularity in myeloid stem cell disorders: impact of age correction.

J. Bennett, N. Tuzuner, J. Rowe, 1994, Leukemia research.

Acute myeloid leukaemia with multilineage dysplasia. .

N. Harris, J. Bennett, G. Flandrin, 2001 .

A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.

J. Doroshow, J. Bennett, H. Muss, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A critical comparison of allogeneic bone marrow transplantation and conventional chemotherapy as treatment for acute nonlymphocytic leukemia.

C. Begg, M. Oken, J. Bennett, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Emerging utility of flow cytometry in the diagnosis of chronic myelomonocytic leukemia.

J. Bennett, W. R. Burack, C. Hudson, 2018, Leukemia research.

Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer.

G. Wampler, J. Bennett, J. Wolter, 1979, Cancer treatment reports.

Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group.

B. Klein, B. Ness, M. Oken, 1998, Blood.

Intravenous myocardial streptokinase infarction

J. Bennett, S. Konstantinides, J. Badenhorst, 1988 .

Increased concentrations of serum free fatty acids falsely increase serum thyroxine as determined by competitive protein-binding.

J. Bennett, P. Pannall, E. Swanepoel, 1977, Clinical chemistry.

Phase II trial of cisplatin in advanced gastric cancer.

P. Engstrom, J. Bennett, S. Vogl, 1984, Cancer treatment reports.

Torsade de pointes induced by sotalol and hypokalaemia.

J. Bennett, S. Konstantinides, J. Gourassas, 1985, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Organization of the clinical activity of geriatric oncology: report of a SIOG (International Society of Geriatric Oncology) task force.

M. Aapro, J. Bennett, S. Monfardini, 2007, Critical reviews in oncology/hematology.

Acute myeloid leukaemia: Introduction. .

N. Harris, J. Bennett, G. Flandrin, 2001 .

Blastic phase of chronic myeloid leukemia (blCML): a proposal for standardization of diagnostic and response criteria.

J. Bennett, R. Silver, Z. Arlin, 1990, Leukemia.

Oncologists' views of cancer patient noncompliance

J. Bennett, G. Morrow, A. Hoagland, 1983, American journal of clinical oncology.

Myocardial imaging with Cc-99m pyrophosphate in patients on adriamycin treatment for neoplasia.

J. Bennett, D. Gordon, A. Chacko, 1977, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis.

J. Bennett, P. Valent, W. Sperr, 2001, Leukemia research.

Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance

F. Solé, M. L. Le Beau, P. Greenberg, 2018, Genes, chromosomes & cancer.

Detection of relapse in acute leukemia: should we discontinue routine bone marrow surveillance?

J. Bennett, 1992, Leukemia.

A phase II study of menogaril (7R-O-methylnogarol) in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group.

J. Bennett, P. Wiernik, T. Leong, 1995, Leukemia.

Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOG.

E. Thiel, T. Haferlach, C. Schoch, 1996, Leukemia & lymphoma.

Acute Myeloid Leukemia with Translocation (8;21). Cytomorphology, Dysplasia and Prognostic Factors in 41 Cases

E. Thiel, C. Schoch, J. Bennett, 1996 .

De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance.

W. Hiddemann, C. Schoch, J. Bennett, 1996, Leukemia.

Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.

L. Kalish, J. Bennett, P. Carbone, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

J. Bennett, T. Smolarek, R. Komrokji, 2009, International journal of hematology.

Weekly oral etoposide in patients with Kaposi's sarcoma associated with human immunodeficiency virus infection: a phase I multicenter trial of the AIDS Clinical Trials Group.

J. Kahn, M. Feldstein, J. Bennett, 1995, Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology.

Erratum: The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study (Annals of Hematology (1992) 65 (162-168))

J. Winter, M. O’connell, J. Bennett, 1993 .

Prognostic implication and characterization of the blast cell population in the myelodysplastic syndrome.

J. Bennett, G. Flandrin, J. Goasguen, 1991, Leukemia research.

Hypocellular acute myeloid leukemia: the Rochester (New York) experience.

J. Bennett, N. Tuzuner, J. Rowe, 1995, Hematologic pathology.

Re: Lee H, et al. An Unusual Case of Myeloperoxidase-Positive Acute Megakaryoblastic Leukemia. Ann Lab Med 2015;35:466-8

J. Bennett, D. Wells, 2015, Annals of laboratory medicine.

Translocation (8;21) in acute myeloid leukemia: when to treat? That is the question!!

J. Bennett, 1995, Leukemia research.

Continuous Infusion Homoharringtonine (NSC 141633) in Refractory Acute Nonlymphocytic Leukemia: An ECOG Pilot Study

M. O’connell, J. Bennett, J. Stewart, 1988, American Journal of Clinical Oncology.

Cytomorphology and Clinical Outcome in 80 Patients with AML M4Eo and Inversion 16

C. Schoch, J. Bennett, W. Ludwig, 1997 .

Prolonged survival after high-dose cytosine arabinoside and amsacrine induction in patients with previously untreated de novo acute nonlymphocytic leukemia.

M. O’connell, J. Bennett, D. Adelstein, 1987, Seminars in oncology.

Leukemia in rochester (NY) a 17‐year experience with an analysis of the role of cooperative group (ECOG) participation

J. Bennett, L. Boros, C. Chuang, 1985, Cancer.

Burkittʼs tumor in the United States

J. Bennett, C. Vogel, P. Carbone, 1969 .

Morphological and cytochemical characteristics of leukaemic promyelocytes.

J. Bennett, V. Liso, 2003, Best practice & research. Clinical haematology.

Cytogenetic Risk Features in MDS-Update and Present State.

C. Steidl, F. Solé, M. L. Beau, 2009 .

Immune markers in adult acute leukemia.

J. Bennett, N. Abramson, J. Deluca, 1976, American journal of clinical pathology.

Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: A study of the Eastern Cooperative Oncology Group (E1993)

J. Bennett, J. Dutcher, E. Paietta, 2005, Leukemia & lymphoma.

Myelodysplastic syndromes classification and risk stratification.

J. Bennett, Ling Zhang, R. Komrokji, 2010, Hematology/oncology clinics of North America.

Drugs Five Years Later: Bleomycin

J. Bennett, S. Reich, 1979 .

Endobronchial metastases from carcinoma of the breast.

J. Bennett, D. B. Ettensohn, R. W. Hyde, 1985, Medical and Pediatric Oncology.

Evaluation of bone marrow toxic reaction in patients treated with allopurinol.

C. Begg, J. Glick, J. Bennett, 1982, JAMA.

Effectiveness of acute nonlymphocytic leukemia induction chemotherapy in acute lymphocytic leukemia.

J. Bennett, P. Cassileth, 1985, Cancer treatment reports.

Results of a Randomized Trial Failing to Confirm Prolonged Disease-FreeSurvival With COPP Chemotherapy

J. Glick, J. Bennett, C. Berard, 2017 .

An atypical case of plasma cell leukemia.

J. Bennett, F. Collichio, C. L. Newman, 1997, Leukemia research.

The hemopoietic colony-stimulating factors: From biology to clinical applications

J. Bennett, 1996 .

Treatment of refractory acute leukaemia with aclacinomycin A.

J. Bennett, J. Rowe, A. Chang, 1989, Bone marrow transplantation.

Classic Papers and Current Comments Highlights of Leukemia Research

K. Sullivan, R. Storb, J. Bennett, 2002 .

The heart and hypothyroidism.

J. Bennett, A. Steyn, 1983, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Treatment of advanced Hodgkin's disease: 10-year experience in the Eastern Cooperative Oncology group.

J. Glick, L. Prosnitz, J. Bennett, 1982, Cancer treatment reports.

Evolving classifications of the myelodysplastic syndromes

J. Bennett, R. Komrokji, 2007, Current opinion in hematology.

Who is WHO in myelodysplastic syndromes? Clinical implications of the WHO classification

J. Bennett, R. Komrokji, 2006, Current hematologic malignancy reports.

Acute leukemia and non-hodgkin lymphoma.

J. Bennett, F. Rosner, M. Zarrabi, 1978, The New England journal of medicine.

B-cell acute lymphoblastic leukemia with L1 morphology and coexistence of t(1;19) and t(14;18) chromosome translocations.

J. Bennett, P. Kouides, P. Phatak, 1994, Cancer genetics and cytogenetics.

Acute myeloid leukemia M4 with inv(16) (p13q22) exhibits a specific immunophenotype with CD2 expression.

J. Bennett, J. Yunis, E. Paietta, 1993, Blood.

Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997

M. Grever, J. Byrd, J. Gribben, 2010 .

Is the association of "cup-like" nuclei with mutation of the NPM1 gene in acute myeloid leukemia clinically useful?

P. Rothberg, J. Bennett, W. R. Burack, 2010, American journal of clinical pathology.

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.

Elizabeth M. Hollinger, Shannon R. McCurdy, H. Deeg, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

“Preleukemic or smoldering” chronic myelogenous leukemia (CML):BCR-ABL1 positive: A brief case report

Mehul R. Patel, J. Bennett, K. O'Dwyer, 2014, Leukemia research reports.

Double valve replacement in a patient with osteogenesis imperfecta.

J. Bennett, J. Gourassas, M. Stevens, 1987, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Granulocyte-macrophage colony-stimulating factor and myelodysplastic syndromes.

J. Bennett, W. Hittelman, W. Piacibello, 1988, The New England journal of medicine.

The Morphological Classification of Acute Lymphoblastic Leukaemia: Concordance among Observers and Clinical Correlations

H. Gralnick, D. Catovsky, J. Bennett, 1981, British journal of haematology.

H. Uno, J. Bennett, M. Tallman, 2010 .

A VARIANT FORM OF HYPERGRANULAR PROMYELOCYTIC LEUKAEMIA (M3)

H. Gralnick, D. Catovsky, J. Bennett, 1980, British journal of haematology.

Large-field, external beam irradiation as a surgical adjuvant for node-positive colon carcinoma: an Eastern Cooperative Oncology Group Pilot Study (PA285).

D. Haller, J. Bennett, H. Merrick, 2000, American journal of clinical oncology.

The role of eosinophil morphology in distinguishing between reactive eosinophilia and eosinophilia as a feature of a myeloid neoplasm

B. Bain, J. Bennett, M. Tomonaga, 2020, British journal of haematology.

B. Bain, M. Cazzola, G. Mufti, 2008, Haematologica.

The Myelodysplastic Syndromes (MDS) Foundation: a retrospective analysis of a nonprofit foundation.

G. Mufti, J. Bennett, T. Hamblin, 2011, Leukemia research.

Modifications in the classification of primary myelodysplastic syndromes: The addition of a scoring system

J. Bennett, J. M. Bennett, J. Woll, 1985, Hematological oncology.

Monosomal karyotype in MDS: explaining the poor prognosis?

C. Steidl, F. Solé, M. L. Beau, 2013, Leukemia.

Understanding the Myelodysplastic Syndromes.

J. Bennett, P. Kouides, Bennett, 1997, The oncologist.

Meeting highlights: therapeutic strategies and supportive care in myelodysplastic syndromes: yesterday, today and tomorrow.

J. Bennett, 1998, Leukemia research.

Malignant melanoma: primary presentation in bone marrow and lymph node.

J. Bennett, M. Basile, J. Harris, 1992, Medical and pediatric oncology.

Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience

D. Neuberg, J. Bennett, E. Paietta, 1998, Leukemia.

Clinical trials with BCNU (NSC-409962) in malignant lymphomas by the Eastern Cooperative Oncology Group.

J. Bennett, R. Lenhard, P. Carbone, 1976, Cancer treatment reports.

Treatment patterns in low-grade non-Hodgkin's lymphomas: a single institution study.

J. Bennett, J. Liesveld, R. Raubertas, 1991, Medical and pediatric oncology.

Activating FLT 3 Mutations in CD 117 / KIT Positive T-Cell Acute Lymphoblastic Leukemias

A. Ferrando, D. Neuberg, A. Look, 2004 .

Mechlorethamine (NSC-762) plus CCNU (NSC-79037) in the treatment of inoperable squamous and large cell carcinoma of the lung.

S. Lagakos, J. Edmonson, J. Bennett, 1976, Cancer treatment reports.

Decoding Bone Marrow Fibrosis in Myelodysplastic Syndrome

J. Bennett, J. Lancet, E. Padron, 2016 .

Pilot studies and new agent programs of the Eastern Cooperative Oncology Group.

M. Zelen, J. Bennett, 1980, Cancer treatment reports.

Survival prediction based on morphology of lymphoblasts.

J. Bennett, G. Segel, M. Klemperer, 1973, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Clinical and chemotherapeutic study of hepatocellular carcinoma in Malaysia. A comparison with African and American patients

J. Bennett, C. Moertel, P. Carbone, 1982, Cancer.

A successful safari.

J. Bennett, 1969, The New England journal of medicine.

Acute approach to orbital lymphatic malformations

J. Bennett, S. Desai, A. Chau, 2020 .

Quality control initiative on the evaluation of the dysmegakaryopoiesis in myeloid neoplasms: Difficulties in the assessment of dysplasia.

B. Bain, J. Bennett, M. Tomonaga, 2016, Leukemia research.

A 3,239 -Patient Combined Eastern Cooperative Oncology Group (ECOG), M.D. Anderson Cancer Center (MDA) Analysis of the Effect of CR vs. Responses < CR on Long-Term Survival in Newly-Diagnosed AML Treated with Ara-C-Containing Regimens: Implications for Targeted Drug Development.

E. Estey, H. Kantarjian, G. Garcia-Manero, 2007 .

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.

O. Abdel-Wahab, R. Levine, J. Bennett, 2016, Blood.

Inappropiate ADH secretion associated with massive vincristine overdosage.

J. Bennett, J. M. Bennett, C. Wakem, 1975, Australian and New Zealand journal of medicine.

Autonomic neuropathy and atypical myocardial infarction in a diabetic clinic population.

J. Bennett, A. Steyn, H. D. Theron, 1987, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

NIH clinical staff conference. Burkitt's tumor.

J. Bennett, P. Carbone, J. Ziegler, 1969, Annals of internal medicine.